What are the recommended guidelines for the diagnosis and management of chronic obstructive pulmonary disease (COPD)?

COPD Management Guidelines

The diagnosis of COPD requires spirometry demonstrating post-bronchodilator FEV1/FVC < 0.7, and management should follow a stepwise pharmacologic approach based on symptom burden and exacerbation risk, with smoking cessation, pulmonary rehabilitation, and long-term oxygen therapy (for severe hypoxemia) being the only interventions proven to reduce mortality. 1, 2

Diagnosis

Spirometry is mandatory - do not diagnose COPD without it 3, 4, 2. Peak flow measurements are inadequate due to poor correlation with FEV1 3.

Diagnostic Criteria:

• Post-bronchodilator FEV1/FVC < 0.7 confirms airflow obstruction 4, 2
• Chest radiograph to exclude other pathologies (cannot positively diagnose COPD) 3
• Arterial blood gases in severe disease to identify hypoxemia/hypercapnia 3

Reversibility Testing:

• A positive response = FEV1 increase of ≥200 ml AND ≥15% from baseline 3
• Substantial bronchodilator response suggests asthma rather than COPD 3
• For moderate-to-severe disease: trial prednisolone 30 mg daily for 2 weeks with pre/post spirometry (10-20% show objective improvement) 3

Special Diagnostic Considerations:

• Age <40 years or family history: screen for α1-antitrypsin deficiency 3
• Symptoms disproportionate to lung function: look for alternative explanations 3
• Frequent infections: exclude bronchiectasis 3

Disease Severity Classification

Severity	FEV1 (% predicted)	Clinical Features
Mild	≥60%	Breathlessness on strenuous exertion, cough ± sputum, minimal signs
Moderate	40-59%	Breathlessness on moderate exertion, cough ± sputum, variable abnormal signs
Severe	<40%	Breathlessness on any exertion/at rest, wheeze and cough prominent, lung overinflation, possible cyanosis/edema/polycythemia [3]

Pharmacologic Management

Mild Disease (FEV1 ≥60%):

• No symptoms: No drug treatment needed 3
• Symptomatic: Short-acting β2-agonist OR inhaled anticholinergic as needed 3
• Stop if ineffective 3

Moderate Disease (FEV1 40-59%):

• Short-acting bronchodilators regularly OR combination of β2-agonist + anticholinergic 3
• Consider corticosteroid trial in all patients 3

Severe Disease (FEV1 <40%):

• Combination therapy: Regular β2-agonist + anticholinergic 3
• Consider corticosteroid trial 3
• Assess for home nebulizer (only after formal assessment by respiratory physician) 3
• Theophyllines have limited value; monitor for side effects if used 3

GOLD 2017 Algorithm (Groups A-D):

The newer classification uses symptom burden and exacerbation history 1:

• Group A (low symptoms, low risk): Single bronchodilator (LABA or LAMA)
• Group B (high symptoms, low risk): LAMA or LAMA + LABA
• Group C (low symptoms, high risk): LAMA or LAMA + LABA
• Group D (high symptoms, high risk): LAMA + LABA or LABA + ICS; consider roflumilast if FEV1 <50% with chronic bronchitis; consider macrolide in former smokers 1

Critical Medication Considerations:

• Optimize inhaler technique - check device appropriateness and technique before changing therapy 3
• Long-acting β2-agonists: limited evidence in 1997 guidelines; only use with objective improvement 3
• No role for: prophylactic antibiotics, cromoglycate, nedocromil, antihistamines, mucolytics, or pulmonary vasodilators 3
• Avoid β-blockers (including eye drops) 3

Non-Pharmacologic Management (Mortality-Reducing Interventions)

Smoking Cessation (Essential at ALL stages):

• Only intervention that prevents accelerated lung function decline 3
• Active cessation programs with nicotine replacement achieve higher sustained quit rates 3
• Cannot restore lost function but prevents further rapid decline 3

Pulmonary Rehabilitation:

• Proven to improve exercise performance and reduce breathlessness 3
• Recommended for moderate-to-severe disease (Groups B, C, D) 3, 1
• Should include exercise training, patient education, nutritional advice, psychosocial support 1
• Combination of constant/interval training with strength training provides best outcomes 1

Long-Term Oxygen Therapy (LTOT):

Prolongs life in hypoxemic patients 3. Prescribe if 3, 1:

• PaO2 ≤7.3 kPa (55 mmHg) or SaO2 ≤88% (confirmed twice over 3 weeks), OR
• PaO2 7.3-8.0 kPa (55-60 mmHg) or SaO2 88% WITH pulmonary hypertension, peripheral edema, or polycythemia (hematocrit >55%)

Other Non-Pharmacologic Measures:

• Exercise encouraged at all stages 3
• Influenza vaccination recommended, especially moderate-to-severe disease 3
• Pneumococcal vaccination (PCV13 and PPSV23) for age ≥65 years; PPSV23 for younger patients with comorbidities 1
• Nutritional support for malnourished patients 1
• Address obesity and poor nutrition 3

Acute Exacerbations

Presentation - Key Symptoms:

• Increased sputum purulence
• Increased sputum volume
• Increased dyspnea
• Increased wheeze
• Chest tightness
• Fluid retention 3

Differential Diagnoses to Exclude:

Pneumonia, pneumothorax, left ventricular failure/pulmonary edema, pulmonary embolus, lung cancer, upper airway obstruction 3

Management Algorithm:

1. Increase or add bronchodilators (ensure proper inhaler device/technique) 3

• β-agonists and/or anticholinergics
• Inhaled route preferred
• Nebulizers usually not required 3

2. Antibiotics if ≥2 of the following:

• Increased breathlessness
• Increased sputum volume
• Development of purulent sputum 3

3. Oral corticosteroids (30 mg daily for 1 week) ONLY if:

• Already on oral corticosteroids, OR
• Previously documented response to corticosteroids, OR
• Airflow obstruction fails to respond to increased bronchodilator dose, OR
• First presentation of airflow obstruction 3

Do NOT continue corticosteroids long-term 3

Follow-Up After Exacerbation:

• Review if patient fails to respond fully (consider chest radiograph and hospital referral) 3
• Use opportunity to reinforce smoking cessation, review lifestyle/activity/weight, optimize medications 3

Monitoring and Follow-Up

Mild-to-Moderate Disease:

• Document diagnosis and spirometry values at diagnosis 3
• Supervise smoking cessation 3
• Document effects of each drug treatment 3
• Monitor spirometry opportunistically - loss of 500 ml over 5 years indicates rapid progression requiring specialist referral 3

Severe Disease:

• Shared care between hospital and GP 3
• Consider respiratory health worker for home visits addressing psychosocial and respiratory problems 3
• Monitor for LTOT eligibility 3

Advanced Disease Considerations

• Pulmonary rehabilitation for symptomatic patients regardless of severity 1
• NIV may be considered in selected patients with pronounced daytime hypercapnia and recent hospitalization 1
• Lung volume reduction surgery or bronchoscopic interventions (endobronchial valves, coils) for selected patients with heterogeneous/homogenous emphysema and significant hyperinflation refractory to medical care 1
• Lung transplantation for very severe COPD without contraindications 1
• End-of-life discussions should occur while patients are stable 1

Common Pitfalls to Avoid

1. Diagnosing COPD without spirometry - peak flow is inadequate 3, 4
2. Continuing ineffective treatments - stop bronchodilators if no benefit 3
3. Poor inhaler technique - always verify before escalating therapy 3
4. Long-term oral corticosteroids after exacerbations - limit to 1 week 3
5. Prescribing LTOT without objective hypoxemia documentation 3
6. Missing comorbidities - cardiovascular disease, anxiety/depression, lung cancer common 1, 2